Traws Pharma, Inc.TRAWEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Traws Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative targeted therapies for rare, orphan, and underserved patient groups with high unmet medical needs. It operates mainly in North American and European markets, advancing a pipeline of candidates for serious, life-threatening health conditions.
Revenue
$2.7M
Gross Profit
N/A
Operating Profit
$-1.2M
Net Profit
$-915.0K
Gross Margin
N/A
Operating Margin
-45.7%
Net Margin
-33.5%
YoY Growth
4694.7%
EPS
$-0.11
Traws Pharma, Inc. Q2 FY2025 Financial Summary
Traws Pharma, Inc. reported revenue of $2.7M (up 4694.7% YoY) for Q2 FY2025, with a net profit of $-915.0K (up 99.3% YoY) (-33.5% margin).
Key Financial Metrics
| Total Revenue | $2.7M |
|---|---|
| Net Profit | $-915.0K |
| Gross Margin | N/A |
| Operating Margin | -45.7% |
| Report Period | Q2 FY2025 |
Traws Pharma, Inc. Quarterly Revenue & Net Profit History
Traws Pharma, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-7.4M | N/A |
| Q3 FY2025 | $0 | — | $-4.0M | N/A |
| Q2 FY2025 | $2.7M | +4694.7% | $-915.0K | -33.5% |
Income Statement
| Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Revenue | $2.7M | $0 | $0 |
| YoY Growth | 4694.7% | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Assets | $15.6M | $12.4M | $10.6M |
| Liabilities | $7.4M | $7.9M | $11.2M |
| Equity | $8.3M | $4.5M | $-629000 |
Cash Flow
| Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Operating CF | $-6.0M | $-4.0M | $-2.8M |